Stock NUVL NUVALENT, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Nuvalent, Inc.

Equities

NUVL

US6707031075

Real-time Estimate Cboe BZX
Other stock markets
 01:32:56 2024-06-05 pm EDT 		5-day change 1st Jan Change
72.85 USD +3.66% Intraday chart for Nuvalent, Inc. +10.13% -1.17%
May. 17 Nuvalent Insider Sold Shares Worth $345,450, According to a Recent SEC Filing MT
May. 16 Nuvalent Gets FDA Breakthrough Therapy Designation for Lung-Cancer Treatment DJ

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Nuvalent Insider Sold Shares Worth $345,450, According to a Recent SEC Filing
Nuvalent Gets Breakthrough Therapy Designation for Lung Cancer Treatment Candidate
Nuvalent, Inc. Receives U.S. FDA Breakthrough Therapy Designation for NVL-655
Nuvalent Q1 Net Loss Widens
Nuvalent, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Nuvalent Insider Sold Shares Worth $2,605,525, According to a Recent SEC Filing
Nuvalent Insider Sold Shares Worth $2,666,555, According to a Recent SEC Filing
Nuvalent Insider Sold Shares Worth $2,458,335, According to a Recent SEC Filing
Nuvalent Insider Sold Shares Worth $2,566,479, According to a Recent SEC Filing
Nuvalent Insider Sold Shares Worth $1,654,311, According to a Recent SEC Filing
Nuvalent Insider Sold Shares Worth $3,032,528, According to a Recent SEC Filing
Nuvalent Insider Sold Shares Worth $1,550,229, According to a Recent SEC Filing
Nuvalent's Non-Small Cell Lung Cancer Drug Candidate Gets FDA Breakthrough Therapy Designation
Nuvalent, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
Nuvalent, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Nuvalent Starts Phase 2 Part of Clinical Trial of Potential Lung Cancer Treatment
Nuvalent, Inc. Initiates the Phase 2 Portion of Alkove-1 Clinical Trial for Patients with Alk-Positive Nsclc and Other Solid Tumors
Nuvalent Outlines Three-Year Product Plan
Nuvalent Insider Sold Shares Worth $378,350, According to a Recent SEC Filing
Nuvalent Insider Sold Shares Worth $2,274,600, According to a Recent SEC Filing
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. NUVL Stock
  4. News Nuvalent, Inc.
  5. Other languages